Learn about our semi-automated chromatography platform for parallel purification of high-quality therapeutic targets.  At PEGS Europe 2023, WuXi AppTec scientists described an automated workflow integrated with a serial size exclusion platform, resulting in a complete purification scheme for the rapid purification of high-quality proteins expressed in E. coli, insect cells, and mammalian cells.  This approach …Read More >

The G12C mutation is one of the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), and oncogenic RAS signaling has been shown to promote an immunosuppressive tumor microenvironment by upregulating PD-L1 expression.  At SITC 2023, WuXi AppTec scientists presented a poster showing that combination therapy of the KRAS G12C inhibitor AMG 510 with …Read More >

To characterize the immunity profile of the most widely used delayed-type hypersensitivity (DTH) models, WuXi AppTec scientists built 2,4-dinitrofluorobenzene (DNFB) and oxazolone-induced DTH models in both BALB/c and C57BL/6 mice with robust ear thickness as the readout. Check out our comprehensive panel of services related to autoimmune and inflammatory diseases

Traditional SPR-based drug discovery efforts in the small-molecule space have revolved around single-use chips for screening and hit-to-lead efforts. Inspired by recent technological advances, we have established simple regenerable protocols that can (1) accommodate target-proteins with common tags such as His- and Avi-, (2) reach sufficient surface density for small-molecule testing, and (3) maintain a …Read More >

Leverage our platform of biophysical methods to accelerate your research on targeted protein degradation. At DDC 2023, WuXi AppTec scientists presented an in-depth panel of assays to support the characterization of bifunctional small molecules. Our cutting-edge services include target protein ubiquitination and degradation assays, techniques to evaluate binary binding, and proximity assays to measure ternary …Read More >

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as …Read More >

In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across a panel of established, in-house diffuse large B-cell lymphoma (DLBCL) patient-derived xenograft (PDX) models. Among our panel of lymphoma PDX models, three represent the germinal center B-cell (GCB) subtype. The authors show that 50% of …Read More >

In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models based on the classification of BRAF mutations. This panel covers all 3 classes of BRAF mutants, including subtypes for which viable therapeutic options remain limited. The authors demonstrate that these PDX models are responsive to …Read More >

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >